Global Hospital Acquired Infection Control Market Segmentation, By Product (Sterilizers, Disinfectors, Endoscope Reprocessors, Microbial Testing Instruments, Reagents, Consumables, Disinfectants, Infection Prevention and Surveillance Software, Others), Application (Disease Testing, Drug-Resistance Testing), Technology (Phenotypic Methods, Genotypic Methods), Disease (Hospital Acquired Pneumonia, Bloodstream Infections, Surgical Site Infections, Gastrointestinal Infections, Urinary Tract Infection, Others), End Users (Hospitals, ICUs, Ambulatory Surgical, Diagnostic Centers, Nursing Homes, Maternity Centers, Others) - Industry Trends and Forecast to 2031
Hospital Acquired Infection Control Market Analysis
Healthcare infrastructure has changed dramatically over the last decade as technology has proliferated and the adoption of innovative medical devices has increased. As the prevalence of various infectious and chronic diseases has increased over the last decade, the need for disinfection and sterilisation equipment has become more pressing than ever.
Hospital Acquired Infection Control Market Size
Global hospital acquired infection control market size was valued at USD 35.04 billion in 2023 and is projected to reach USD 74.56 billion by 2031, with a CAGR of 9.90% during the forecast period of 2024 to 2031.
Report Scope and Market Segmentation
|
Attributes
|
Hospital Acquired Infection Control Key Market Insights
|
|
Segmentation
|
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Key Market Players
|
Olympus Corporation (Japan), Cantel Medical (US), Getinge AB (Sweden), STERIS plc (US), Belimed (Switzerland), STEELCO S.p.A. (Italy), ASP (US), BD (US), Crosstex International, Inc. (US), Diversey, Inc (US), MMM Group (US), 3M (US), bioMérieux SA (France), Sterigenics U.S., LLC (US), Cepheid (US), Dentsply Sirona (US), Mindray Bio-Medical Electronics Co., Ltd (China), Randox Laboratories Ltd. (UK), Ortho Clinical Diagnostics (US), Nova Biomedical (UK) and Sysmex Corporation (Japan)
|
Hospital Acquired Infection Control Market Definition
Hospital-Acquired Infection (HAI) Control refers to the systematic practices and protocols aimed at preventing infections acquired within healthcare settings. It includes measures like hand hygiene, sterilization, isolation, and the judicious use of antibiotics to curb infections among patients and healthcare workers. Effective HAI control minimizes infection transmission, improves patient outcomes, and reduces healthcare costs. Continuous monitoring, education, and adherence to guidelines are key components of these efforts.
Hospital Acquired Infection Control Market Dynamics
Drivers
Major factors that are expected to boost the growth of the hospital acquired infection control market in the forecast period are as follows:
- Rise in the prevalence of hospital-acquired infections (HAIs)
As a result of a lack of preventive measures, there is an increase in the number of hospital-acquired infections. In hospitals, infections are frequently caused by contaminated medical equipment and devices will further accelerate the demand for the hospital acquired infection control market.
- Growing number of surgical procedures
Over the years, there has been a significant increase in the number of surgical procedures performed worldwide as a result of lifestyle diseases, the growing geriatric population, and the increasing incidence of spinal injuries are the major drivers that will enhance the growth of market.
- Growing of elderly population
Chronic diseases such as cardiovascular disease, cancer, diabetes, and other autoimmune diseases are becoming more common as the world's population ages which is further anticipated to propel the growth of the hospital acquired infection control market.
Opportunities
In addition, the growing adoption of single-use medical nonwovens and devices are further estimated to provide potential opportunities for the growth of the hospital acquired infection control market in the coming years.
Restraints/Challenges
On the other hand, the increased cost of endoscopy reprocessing and inadequate reimbursement in the advancing countries is further projected to impede the growth of the hospital acquired infection control market in the targeted period. However, the difficulties regarding the hospital-acquired infection control procedures might further challenge the growth of the hospital acquired infection control market in the near future.
This hospital acquired infection control market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hospital acquired infection control market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Covid-19 Impact on Hospital Acquired Infection Control Market
The pandemic of COVID-19 has had a huge impact on the hospital acquired infection control market. The pandemic has wreaked havoc on healthcare systems around the world, with hospitals becoming overburdened as the number of patients continues to rise. Temporary hospitals were also established to handle the increasing number of cases. As a result of the increasing cases of hospital acquired infection in hospital settings, the spread of COVID-19 has resulted in an increase in demand for HAI services. However, in the aftermath of the pandemic, the severe consequences of COVID-19, such as hospitalisation, may help the hospital-acquired infection control industry gain traction in the coming years.
Global Hospital Acquired Infection Control Market Scope
The hospital acquired infection control market is segmented on the basis of product, application, technology, disease and end users. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Sterilizers
- Disinfectors
- Endoscope Reprocessors
- Microbial Testing Instruments
- Reagents
- Consumables
- Disinfectants
- Infection Prevention and Surveillance Software
- Others
On the basis of product, the hospital acquired infection control market is segmented into sterilizers, disinfectors, endoscope reprocessors, microbial testing instruments, reagents, consumables, disinfectants, infection prevention and surveillance software and others. Sterilizers have been further sub segmented into heat sterilization equipment, low temperature sterilization equipment, radiation sterilization equipment and others. Heat sterilization equipment is further sub segmented into moist heat sterilization equipment and dry heat sterilization equipment. Disinfectors have been further sub segmented into washer disinfector and flusher disinfector. Endoscope reprocessors have been further sub segmented into single basin endoscopic reprocessors and dual basin endoscopic reprocessors. Microbial testing instruments have been further sub segmented into automated microbial identification systems, polymerase chain reaction (PCR) instruments, mass spectrometers, microarrays, polystainers, flow cytometers and others. Disinfectants have been further sub segmented into type and formulation. Type has been further sub segmented into hand disinfectants, skin disinfectants, instrument disinfectants and surface disinfectants/disinfectant robots. Formulation has been further sub segmented into disinfectant wipes, disinfectant liquids and disinfectant sprays.
Application
- Disease Testing
- Drug-Resistance Testing
On the basis application, the hospital acquired infection control market is segmented into disease testing and drug-resistance testing.
Technology
- Phenotypic Methods
- Genotypic Methods
On the basis of technology, the hospital acquired infection control market is segmented into phenotypic methods and genotypic methods. Phenotypic methods has been further sub segmented into phage-based assays, colorimetric methods and nitrate reductase assay. Genotypic methods has been further sub segmented into DNA sequencing, solid-phase hybridization techniques, polymerase chain reaction (PCR) techniques and microarrays.
Disease
- Hospital Acquired Pneumonia
- Bloodstream Infections
- Surgical Site Infections
- Gastrointestinal Infections
- Urinary Tract Infection
- Others
On the basis of disease, the hospital acquired infection control market is segmented into hospital acquired pneumonia, bloodstream infections, surgical site infections, gastrointestinal infections, urinary tract infections (UTI) and others.
End Users
- Hospitals
- ICUs
- Ambulatory Surgical
- Diagnostic Centers
- Nursing Homes
- Maternity Centers
- Others
On the basis of end users, the hospital acquired infection control market is segmented into hospitals, intensive care units (ICUs), ambulatory surgical, diagnostic centers, nursing homes, maternity centers and others.
Hospital Acquired Infection Control Market Regional Analysis
The hospital acquired infection control market is analysed and market size insights and trends are provided by country, product, application, technology, disease and end users as referenced above.
The countries covered in the hospital acquired infection control market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the hospital acquired infection control market due to the rise in the major healthcare facilities and authorities on the prevention and spread of any infections originating from different healthcare facilities. Furthermore, the increase in the awareness of hospital acquired infection will further boost the growth of the hospital acquired infection control market in the region during the forecast period.
Asia-Pacific is projected to observe significant amount of growth in the hospital acquired infection control market due to the rise in the incidence of hospital acquired infections and advancing healthcare infrastructure in low and middle-income countries. Moreover, the newborns in the advancing countries are at a higher risk of contracting healthcare-associated infections than in developed countries which is further anticipated to propel the growth of the hospital acquired infection control market in the region in the coming years.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The hospital acquired infection control market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for hospital acquired infection control market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the hospital acquired infection control market. The data is available for historic period 2010-2020.
Hospital Acquired Infection Control Market Share
The hospital acquired infection control market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hospital acquired infection control market.
Hospital Acquired Infection Control Market Leaders Operating in the Market Are:
- Olympus Corporation (Japan)
- Cantel Medical (US)
- Getinge AB (Sweden)
- STERIS plc (US)
- Belimed (Switzerland)
- STEELCO S.p.A. (Italy)
- ASP (US)
- BD (US)
- Crosstex International, Inc. (US)
- Diversey, Inc (US)
- MMM Group (US)
- 3M (US)
- bioMérieux SA (France)
- Sterigenics U.S., LLC (US)
- Cepheid (US)
- Dentsply Sirona (US)
- Mindray Bio-Medical Electronics Co., Ltd (China)
- Randox Laboratories Ltd. (UK)
- Ortho Clinical Diagnostics (US)
- Nova Biomedical (UK)
- Sysmex Corporation (Japan)
Latest Developments in Hospital Acquired Infection Control Market
- In September 2021, Sodexo has expanded its partnership with Ecolab in the United States for the control of hospital-acquired infections through the Protecta Plus programme. This programme was created to reduce infection risk in hospitals and healthcare facilities by utilising Ecolab's Bioquell hydrogen peroxide vapour technology
SKU-